What are Isogenic Cell Lines?

Cell lines are formed of cells that are able to grow indefinitely if the right conditions are met, and these can be from various sources. These cell lines are widely used in the laboratory, from studying cancer to testing potential novel treatments.

Image Credits: Evgeniy Kalinovskiy / Shutterstock.comImage Credits: Evgeniy Kalinovskiy / Shutterstock.com

Are all cells the same?

Isogenic refers to a population with essentially identical genes. There are techniques available that can modify the DNA of cells, and this can then be used as a disease model. For example, cancer cells often have changes in their DNA, and thus this can be copied into an isogenic cell line.

Being able to modify the DNA means that it is possible to have two isogenic cell lines: one with the changes related to cancer development, and the other without those changes. This makes comparisons easier, as it can be difficult to find related cells that express genes in the same way.

How are they used?

Regulating gene expression in cell lines

Liu and co. devised a system where zinc finger protein transcription factors specific to genes of interest were used to induce gene expression in target cells. This system has high specificity, so the likelihood of other genes being affected by the zinc finger protein transcription factor is low. The expression of the zinc finger protein transcription factor can also be made inducible, so that it is possible to control when the gene of interest is activated.

The authors targeted the human parathyroid hormone receptor 1 (PTHR1), which is a G protein-coupled receptor that has a role in calcium homeostasis and bone metabolism. A zinc finger protein transcription factor that targets PTHR1 was identified, and used to induce its expression in HEK293 cells, which do not normally express PTHR1.

When the zinc finger protein transcription factor was induced, the HEK293 cells began to express PTHR1. The activity of the expressed PTHR1 was confirmed by increase in the levels of cAMP produced by the cells. The authors then used known PTHR1 ligands, and this led to the reduction in cAMP levels, thus showing that its function was reduced. The authors concluded that this approach can be used to study effects of potential therapeutic compounds on target genes.

Studying DNA mismatch repair deficiency

Errors during DNA replication can lead to changes in the DNA, including single base mismatches, base modification, and small insertion-deletion loops. To counteract the affects of these errors, DNA mismatch repair systems exists in these cells. However, these DNA mismatch repair systems can become defective, allowing these DNA changes to persist and potentially lead to cancer. In fact, it is estimated that up to 20% of solid tumors and hematologic cancers have DNA mismatch repair system deficiencies.

Bailis and co. derived an isogenic cell line system to investigate deficiency of DNA mismatch repair systems. In the study, the authors used inducible short hairpin RNA (shRNA) to prevent expression of the gene MLH1, a gene that is part of the DNA mismatch repair system. Here, when the shRNA is induced, this prevents the expression of MLH1, thus inactivating it. As the shRNA is inducible, this gave the authors the opportunity to study differences seen when MLH1 was active compared to when it was inactive.

One change the authors observed was the induction of microsatellite instability in cells when MLH1 was inactive. Microsatellite instability is another change in DNA, where repeated nucleotide sequences are either gained or lost, and the authors observed 1-3 nucleotide shifts at the BAT-26 mononucleotide repeat. However, this did not change the global gene expression pattern in the cell lines.

Predictive cancer biomarker discovery

In cancer biology, predictive biomarkers give information about the effect of treatment. Haagensen and co. utilized isogenic cell lines to seek out potential predictive biomarkers in response to four therapeutic drugs.

The authors found that the response varied according to how the cells were cultured. For example, in 2D culture they found that KRAS+/- and PIK3CA+/- cells were more sensitive to MEK inhibitors compared to their isogenic parental cells or other mutants. However, in a 3D system KRASG13D/- and PIK3CAE545K/- xenografts were sensitive to one of the MEK inhibitors, but “tumors” derived from parental cells were not sensitive at all.

This shows that, by the use of isogenic cell lines, response to MEK inhibitors are not only influenced by mutations in KRAS and PIK3CA, but also by how these cells are grown.


sciencedirect.com. Cell Lines https://www.sciencedirect.com/topics/neuroscience/.

Gillet, J.-P. et al. (2013) The Clinical Relevance of Cancer Cell Lines. Journal of the National Cancer Institute https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691946/

merriam-webster.com. Isogenic https://www.merriam-webster.com/dictionary/isogenic

amsbio.com. Isogenic Cell Lines http://www.amsbio.com/isogenic-cell-lines.aspx

Liu, P.-Q. et al. (2005) Isogenic Human Cell Lines for Drug Discovery: Regulation of Target Gene Expression by Engineered Zinc-Finger Protein Transcription Factors. Journal of Biomolecular Screening https://journals.sagepub.com/doi/abs/10.1177/1087057104272663

Bailis, J. M. et al. (2013) An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency. PLOS One journals.plos.org/plosone/article?id=10.1371/journal.pone.0078726

Oldenhuis, C. N. et al. (2008) Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer https://www.ncbi.nlm.nih.gov/pubmed/18396036

Haagensen, E. J. et al. (2016) Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer https://www.sciencedirect.com/science/article/pii/S0959804915011569

Further Reading

Last Updated: Jul 1, 2023

Dr. Maho Yokoyama

Written by

Dr. Maho Yokoyama

Dr. Maho Yokoyama is a researcher and science writer. She was awarded her Ph.D. from the University of Bath, UK, following a thesis in the field of Microbiology, where she applied functional genomics to Staphylococcus aureus . During her doctoral studies, Maho collaborated with other academics on several papers and even published some of her own work in peer-reviewed scientific journals. She also presented her work at academic conferences around the world.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Yokoyama, Maho. (2023, July 01). What are Isogenic Cell Lines?. News-Medical. Retrieved on July 14, 2024 from https://www.news-medical.net/life-sciences/What-are-Isogenic-Cell-Lines.aspx.

  • MLA

    Yokoyama, Maho. "What are Isogenic Cell Lines?". News-Medical. 14 July 2024. <https://www.news-medical.net/life-sciences/What-are-Isogenic-Cell-Lines.aspx>.

  • Chicago

    Yokoyama, Maho. "What are Isogenic Cell Lines?". News-Medical. https://www.news-medical.net/life-sciences/What-are-Isogenic-Cell-Lines.aspx. (accessed July 14, 2024).

  • Harvard

    Yokoyama, Maho. 2023. What are Isogenic Cell Lines?. News-Medical, viewed 14 July 2024, https://www.news-medical.net/life-sciences/What-are-Isogenic-Cell-Lines.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New antibiotic lolamicin shows promise in fighting drug-resistant infections